K. Tokushige

Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia

S. Grupp, I. Kato, S. Adachi, 2019, International Journal of Hematology.

Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

Y. Ando, T. Doi, H. Minami, 2020, Cancer science.

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma

K. Akashi, K. Izutsu, Koji Kato, 2020, International Journal of Clinical Oncology.

Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset

K. Kiura, M. Satouchi, S. Matsumoto, 2017, Japanese journal of clinical oncology.

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors

Makoto Nishio, Haruyasu Murakami, Takashi Seto, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors

Y. Ando, Y. Hirashima, T. Shibata, 2016, Cancer Chemotherapy and Pharmacology.

Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial

K. Akashi, M. Dreyling, S. Schuster, 2022, International Journal of Hematology.

Phase I study of anti‐CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B‐cell non‐Hodgkin lymphoma

M. Ogura, K. Tobinai, K. Ando, 2012, Cancer science.

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset

K. Kiura, M. Satouchi, S. Matsumoto, 2018, Japanese journal of clinical oncology.

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Young Hak Kim, S. Matsumoto, M. Maemondo, 2018, Cancer science.

The efficacy of ceritinib for alk-rearranged non-small cell lung cancer previously treated with alectinib - An analysis of Japanese and global Phase I studies

G. Toyokawa, M. Nishio, H. Murakami, 2017 .

Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.

H. Akaza, S. Naito, Se-Hoon Lee, 2012, Japanese journal of clinical oncology.